Hematopoiesis News Volume 6.31 | Aug 11 2015

    0
    22

    Hematopoiesis News 6.31 August 11, 2015

    Hematopoiesis News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  HN on Twitter

     
    TOP STORY
    Arginine Methyltransferase PRMT5 Is Essential for Sustaining Normal Adult Hematopoiesis
    Investigators generated Prmt5 conditional KO mice to evaluate the contribution of PRMT5 to adult hematopoiesis. Loss of PRMT5 triggered an initial but transient expansion of hematopoietic stem cells; however, Prmt5 deletion resulted in a concurrent loss of hematopoietic progenitor cells, leading to fatal BM aplasia. [J Clin Invest] Full Article
    Learn more about our standardized tools for cord blood banking

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Altered Mesenchymal Niche Cells Impede Generation of Normal Hematopoietic Progenitor Cells in Leukemic Bone Marrow
    Researchers focused on murine bone mesenchymal stem cells and their supporting function for normal hematopoietic cells in Notch1-induced acute T cell lymphocytic leukemia mice. [Leukemia] Abstract

    Overlapping Requirements for Tet2 and Tet3 in Normal Development and Hematopoietic Stem Cell Emergence
    Investigators identified Tet2 and Tet3 as the major 5-methylcytosine dioxygenases in the zebrafish embryo and uncovered a combined requirement for Tet2 and Tet3 in hematopoietic stem cell emergence. [Cell Rep]
    Full&nbspArticle
    | Graphical Abstract

    Targeted Sequencing Identifies Association between IL7R-JAK Mutations and Epigenetic Modulators in T-Cell Acute Lymphoblastic Leukemia
    To determine the frequency and co-occurrence of mutations in T-cell acute lymphoblastic leukemia, investigators performed targeted re-sequencing of 115 genes across 155 diagnostic samples. [Haematologica] Abstract | Full Article

    MicroRNA-320a Acts as a Tumor Suppressor by Targeting BCR/ABL Oncogene in Chronic Myeloid Leukemia
    The authors found that microRNA (miR)-320a expression was reduced in K562 and in chronic myeloid leukemia cancer stem cells. They found that miR-320a inhibited K562 cell migration, invasion, proliferation and promoted apoptosis by targeting BCR/ABL oncogene. [Sci Rep] Full Article

    Hematopoietic Progenitors Are Required for Proper Development of Coronary Vasculature
    As a model for hematopoietic cell deficient animals, scientists used Runx1 knockout embryos and Vav1-cre; R26-DTA embryos, the latter of which genetically ablates 2/3 of CD45+ hematopoietic cells. Both Runx1 knockout embryos and Vav1-cre; R26-DTA embryos revealed disorganized, hypoplastic microvasculature of coronary vessels on section and whole-mount stainings. [J Mol Cell Cardiol] Abstract

    Promotion of Erythropoietic Differentiation in Hematopoietic Stem Cells by SOCS3 Knock-Down
    Researchers found that suppressor of cytokine signaling 3 (SOCS3) knockdown induced erythroid expansion in hematopoietic stem cells (HSCs). Conversely, Ectopic expression of SOCS3 in progenitor cells blocked erythroid expansion and erythroid colony formation of HSCs. [PLoS One] Full Article

    CLINICAL RESEARCH

    Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ by Conditioning Strategies
    Researchers evaluated outcomes of 1041 adult recipients at two centers between 2006 and 2013 and investigated how the effect of sex-mismatch differed in myeloablative, reduced-intensity, and non-myeloablative total lymphoid irradiation with anti-thymocyte globulin conditioning. [Haematologica] Abstract | Full Article

    Treosulfan-Based Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Children with Non-Malignant Diseases
    A retrospective analysis was performed of children registered in the EBMT database, who received treosulfan before hematopoietic stem cell transplantation, to identify possible dose-related toxicity and determine the incidence of engraftment, treatment-related mortality and overall survival. [Bone Marrow Transplant] Abstract

    Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GvHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)
    Researchers performed a Phase II study of atorvastatin for acute GvHD prophylaxis when given to allogeneic HSCT recipients and their HLA-matched sibling donors. [Biol Blood Marrow Transplant] Abstract

    Standardize Your CFU Assays With STEMvision for Automated CFU Assay Imaging and Analysis

     
    REVIEWS
    Fetal Hematopoietic Stem Cells Are the Canaries in the Coal Mine that Portend Later Life Immune Deficiency
    The authors describe the process of fetal hematopoiesis and provide an overview of the intrauterine environmental and endocrine-disrupting compounds that disrupt this process. They describe research opportunities for fetal hematopoietic stem cells as potential sentinels of later-life blood and immune system disorders. [Endocrinology] Abstract

    Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

     
    INDUSTRY NEWS
    Cell Therapy Catapult Awards Major Contract to Cellular Therapeutics Limited to Accelerate WT1 Clinical Program
    The Cell Therapy Catapult has awarded a manufacturing contract to Cellular Therapeutics Limited, to accelerate its clinical program to develop an engineered T cell treatment for blood cancers such as acute myeloid leukaemia and myelodysplastic syndrome. [Cellular Therapeutics Limited] Press Release

    Newcastle Gets £5 Million to Boost Drug Development
    Cancer Research UK’s Drug Discovery Committee has awarded Newcastle University’s Northern Institute of Cancer Research £5 million to bring more cancer drugs to clinical trials. [Cancer Research UK] Abstract

    From our sponsor:
    Want to learn more about ALDH in breast cancer treatment response?
    Listen to the podcast.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW ISCBC 2015: International Stem Cell Biology Conference
    October 11-12, 2015
    Osaka, Japan

    Visit our events page to see a complete list of events in the hematopoiesis community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Research Associate – Pharmacogenomics (St. Jude Children’s Research Hospital)

    Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)

    Postdoctoral Fellow – Hematopoiesis (University Hospital of Cologne)

    Postdoctoral Fellow – Hematopoietic Regeneration and Myeloid Malignancies (Weill-Cornell Medical College)

    Postdoctoral Position – Hematopoietic Stem and Progenitor Cell Assays (Weill Cornell Medical School)

    Research Associate – Cell Biology (Editas Medicine)

    Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

    Postdoctoral Position – Hematopoietic Stem Cell Transplantation (St. Jude Children’s Research Hospital)

    Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Hematopoiesis News: Archives | Events | Contact Us